Trademark: OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)
Put your brand on the blockchain and timestamp its proof of existence at wikitrademarks.io
Mark Identification
OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)
Click here to search for trademarks similar to OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)
Proof of use for OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)
We do not have any records of a proof of use for OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW) at this moment.
Click here to add a proof of use for OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)
Possible trademark infringements of OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW)
Basic Information
- Serial Number
- 97342302
- Filing Date
- 01 Apr 2022
- Registration Number
- 7130293
- Registration Date
- 08 Aug 2023
- Mark Drawing Code
- 3
Classifications
Declare the trademark use of OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW) on the blockchain with WikiTrademarks.io.
- First use anywhere
- OPDUALAG (NIVOLUMAB AND RELATLIMAB-RMBW) was first used on 22 Mar 2022 for the primary classification of goods and services, international, 005 (Pharmaceuticals)
- First use in commerce
- There is no first use of this trademark in commerce detected yet.
- Status Code
- 6
- International Code
- 005
- US Codes
- 005; 006; 018; 044; 046; 051; 052
Ownership history of this trademark/brand
1. Bristol-Myers Squibb Company Princeton NJ
2. Bristol-Myers Squibb Company Princeton NJ
3. Bristol-Myers Squibb Company New York NY
Correspondent
- Marilyn F. Kelly
- BRISTOL-MYERS SQUIBB COMPANY
- P.O. BOX 4000
- TRADEMARK DEPT., MAILSTOP D.4243
Put your brand on the blockchain and timestamp its proof of existence at Wikitrademarks.io